

Medicare Part B Utilization Management Review

Document Number: MUM-100

Last Review Date: 08/01/2025

Date of Origin: 08/01/2023

Dates Reviewed: 08/2023, 8/2024, 01/2025, 08/2025

Overview

A minimum 90-day transition period shall be provided when an enrollee undergoing an active course of treatment switches to a new Medicare Advantage (MA) plan.

Utilization management review for Medicare Part B occurs via a stepwise approach as follows:

1. Determination of “reasonable and necessary”
 - a. Refer to the [Medicare Coverage Database](#) (MCD) for a national coverage determination (NCD) or local coverage determination (LCD) from the Medicare Administrative Contractor (MAC) for the jurisdiction.
 - b. In the absence of an NCD, LCD, or original Medicare guidance OR if the aforementioned do not address the requested use AND do not preclude coverage, then review occurs via one of the following:
 - i. The [FDA-approved](#) full product label (not highlights of prescribing information) is referenced for ALL the following:
 - Indication (including age restrictions)
 - Dose and frequency
 - Duration of therapy (if limited)
 - Boxed warnings
 - Contraindications (with the exception of hypersensitivity to the requested product)
 - Warnings and Precautions (with the exception of those which would only become apparent/applicable upon receipt of the product as this occurs subsequent to the pre-service determination).
 - ii. Off-label use (inclusive of dose, frequency, and duration) reference the following:
 - Oncology
 - CMS-supported compendia (i.e., NCCN, Clinical Pharmacology, Lexicomp Lexi-Drugs, Micromedex DrugDex (Merative Micromedex), & AHFS-DI) or published peer-reviewed literature
 - Non-Oncology
 - CMS-supported compendia (i.e., NCCN, Clinical Pharmacology, Lexicomp Lexi-Drugs, Micromedex DrugDex (Merative Micromedex), & AHFS-DI), authoritative medical literature and/or accepted standards of medical practice.
2. Once “reasonable and necessary” has been determined, refer to the Medicare Part B Step Therapy document for preferred agents (as applicable).
 - a. Exceptions to step therapy include any of the following:
 - i. Use of the non-preferred product in the preceding 365 days.

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

- ii. Documented failure, contraindication, or intolerance to [CLIENT- specific: all, one, two, etc.] preferred products.
 - iii. Documentation that all preferred products are likely to be ineffective or cause an adverse reaction.
 - iv. The medically accepted indication for use is not shared amongst products by either FDA labeling or CMS-recognized compendia or clinical literature.
3. The authorization validity period must conform to that specified by CMS or the MAC. In the absence of such, it shall be determined based upon the prescriber's anticipated course of therapy, unless there is a superseding limitation to the duration in the source used to determine reasonable and necessary (refer to 1.b. and 1.c. above).
4. Should the anticipated course of therapy not be provided, provider outreach shall occur to obtain such. In the event that this information has not been obtained within the preservice organization determination processing timeframe (CMS-4180-F), the anticipated course of therapy applied will conform to that established for other drugs via one of the following: NCD, LCD, FDA labeling, compendia, or industry standard. The course of therapy may be amended post-determination upon clarification from the provider.
5. Requests for continuation of therapy shall assess beneficial response to therapy and the absence of unacceptable toxicities for a medically accepted indication.
6. The clinician reviewer considers all relevant aspects of the case and patient-specifics when making the determination. The clinician reviewer may exercise clinical judgment and apply it to the pre-service determination. Such applications will be clearly documented in the case file notes.

References

1. Lexi-Drugs. Lexicomp [Internet]. Hudson, OH: Wolters Kluwer Health, Inc. Available from: <http://online.lexi.com>
2. Merative Micromedex (DRUGDEX). Micromedex [Internet]. Greenwood Village, CO: Truven Health Analytics, Inc. Available from: <http://www.micromedexsolutions.com>
3. Gold Standard, Inc. Clinical Pharmacology [Internet]. Philadelphia, PA: Elsevier. Available from: <https://www.clinicalkey.com/pharmacology/>
4. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc. Available from: <https://www.ahfscdi.com/login>
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org.